2026 Global: Automated Blood Cell Counter Market -Competitive Review (2032) report
Description
The 2026 Global: Automated Blood Cell Counter Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for automated blood cell counter market by geography and historical trend. The scope of the report extends to sizing of the automated blood cell counter market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The automated blood cell counter market is dominated by several global diagnostics and life-science companies that supply hematology analyzers, imaging-based counters, and integrated laboratory platforms; Sysmex Corporation leads with a broad portfolio of high-throughput hematology systems and clinical lab automation widely used in hospitals and reference labs. Abbott Laboratories supplies Coulter-principle hematology analyzers that emphasize throughput and routine clinical performance in decentralized and central labs. Beckman Coulter (Danaher) is a major player in flow- and impedance-based hematology instruments and has strong adoption in high-volume clinical settings thanks to its DxH line and integrated workflows. Thermo Fisher Scientific offers a mix of benchtop and automated cell counters, combining image-based enumeration, AI-assisted analysis, and enterprise data management for research and clinical customers. Roche Diagnostics (F. Hoffmann‑La Roche Ltd.) competes with integrated solutions that link hematology results into broader laboratory information systems and consolidated diagnostic platforms favored by hospital networks.
Major life-science and instrument manufacturers also shape the market through specialized imaging, benchtop, and point-of-care counters: Bio‑Rad Laboratories provides reagents, imaging instruments, and consumables aimed at research and QC workflows where reproducibility is critical. Agilent Technologies and PerkinElmer supply high-precision optical and imaging systems tailored to research, high-throughput screening, and cell-therapy manufacturing environments. Sartorius (including Nexcelom/Revvity lineage) and Countstar focus on fluorescence image‑based counters and cell‑therapy oriented instruments that emphasize multiparameter viability and concentration readouts for bioprocess and regenerative-medicine users. Chemometec, Horiba Medical, and smaller specialized firms (e.g., Logos Biosystems, DeNovix) complement larger vendors by offering niche high‑throughput, portable, or cost‑effective analyzers that target academia, CDMOs, and point‑of‑care markets where footprint and ease of use drive procurement decisions.
Competitive dynamics in the automated blood cell counter market are defined by innovation in image-based analytics, AI/debris rejection algorithms, integration with bioprocess control systems, and regulatory-cleared clinical workflows; Thermo Fisher and Beckman have recently emphasized AI and robotic integration to improve unattended runs and data quality. Consolidated diagnostics companies such as Roche, Abbott, and Sysmex leverage broad service networks and LIS connectivity to sell into hospital systems, while niche vendors win in regenerative‑medicine and research cores through specialized assays and higher-content morphological outputs. Market growth is propelled by rising chronic disease prevalence, expansion of cell‑based therapies, and demand for standardized, audit‑ready enumeration in GMP environments, encouraging both incumbents and new entrants to prioritize interoperability, throughput scaling, and multi-parameter measurement capabilities.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for automated blood cell counter market by geography and historical trend. The scope of the report extends to sizing of the automated blood cell counter market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The automated blood cell counter market is dominated by several global diagnostics and life-science companies that supply hematology analyzers, imaging-based counters, and integrated laboratory platforms; Sysmex Corporation leads with a broad portfolio of high-throughput hematology systems and clinical lab automation widely used in hospitals and reference labs. Abbott Laboratories supplies Coulter-principle hematology analyzers that emphasize throughput and routine clinical performance in decentralized and central labs. Beckman Coulter (Danaher) is a major player in flow- and impedance-based hematology instruments and has strong adoption in high-volume clinical settings thanks to its DxH line and integrated workflows. Thermo Fisher Scientific offers a mix of benchtop and automated cell counters, combining image-based enumeration, AI-assisted analysis, and enterprise data management for research and clinical customers. Roche Diagnostics (F. Hoffmann‑La Roche Ltd.) competes with integrated solutions that link hematology results into broader laboratory information systems and consolidated diagnostic platforms favored by hospital networks.
Major life-science and instrument manufacturers also shape the market through specialized imaging, benchtop, and point-of-care counters: Bio‑Rad Laboratories provides reagents, imaging instruments, and consumables aimed at research and QC workflows where reproducibility is critical. Agilent Technologies and PerkinElmer supply high-precision optical and imaging systems tailored to research, high-throughput screening, and cell-therapy manufacturing environments. Sartorius (including Nexcelom/Revvity lineage) and Countstar focus on fluorescence image‑based counters and cell‑therapy oriented instruments that emphasize multiparameter viability and concentration readouts for bioprocess and regenerative-medicine users. Chemometec, Horiba Medical, and smaller specialized firms (e.g., Logos Biosystems, DeNovix) complement larger vendors by offering niche high‑throughput, portable, or cost‑effective analyzers that target academia, CDMOs, and point‑of‑care markets where footprint and ease of use drive procurement decisions.
Competitive dynamics in the automated blood cell counter market are defined by innovation in image-based analytics, AI/debris rejection algorithms, integration with bioprocess control systems, and regulatory-cleared clinical workflows; Thermo Fisher and Beckman have recently emphasized AI and robotic integration to improve unattended runs and data quality. Consolidated diagnostics companies such as Roche, Abbott, and Sysmex leverage broad service networks and LIS connectivity to sell into hospital systems, while niche vendors win in regenerative‑medicine and research cores through specialized assays and higher-content morphological outputs. Market growth is propelled by rising chronic disease prevalence, expansion of cell‑based therapies, and demand for standardized, audit‑ready enumeration in GMP environments, encouraging both incumbents and new entrants to prioritize interoperability, throughput scaling, and multi-parameter measurement capabilities.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
